Currently, EPZ5676 is under active investigation in two clinical trials, testing its efficacy in relapsed and therapy refractory AML patients with MLL-rearrangements in combination with 5-azacitidine (NCT03701295) and in patients with newly diagnosed MLL-rearranged AML in combination with standard induction chemotherapy (NCT03724084). Here, KMT2A is linked to acute myeloid leukemia.